Indications for breast cancer should be left to EOC our Chinese partner.
Management is concentrating on the most likely to be approved and profitable indications.
IMM has world wide patents for eftilagimod/PD1 combination therapy. GSK, BMS and others will want in on the action.
lag525 is another check point inhibitor. No reason it couldn’t be used with eftilagimod/pd1 therapy
- Forums
- ASX - By Stock
- Ann: Appendix 4E & 2022 Full Year Statutory Accounts
Indications for breast cancer should be left to EOC our Chinese...
-
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMM (ASX) to my watchlist
|
|||||
Last
37.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $537.4M |
Open | High | Low | Value | Volume |
37.0¢ | 38.3¢ | 36.5¢ | $1.060M | 2.841M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 48648 | 36.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
37.0¢ | 13814 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 48648 | 0.365 |
7 | 164694 | 0.360 |
4 | 31498 | 0.355 |
7 | 161310 | 0.350 |
3 | 12221 | 0.345 |
Price($) | Vol. | No. |
---|---|---|
0.370 | 13814 | 2 |
0.375 | 175836 | 7 |
0.380 | 137322 | 5 |
0.385 | 53062 | 4 |
0.390 | 197301 | 5 |
Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online